Last ¥1,432 JPY
Change Today +22.00 / 1.56%
Volume 69.9K
4573 On Other Exchanges
Symbol
Exchange
Tokyo
As of 2:00 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

r-tech ueno ltd (4573) Snapshot

Open
¥1,364
Previous Close
¥1,410
Day High
¥1,450
Day Low
¥1,357
52 Week High
07/17/13 - ¥2,651
52 Week Low
05/21/14 - ¥945.00
Market Cap
27.6B
Average Volume 10 Days
138.4K
EPS TTM
¥55.07
Shares Outstanding
19.3M
EX-Date
03/27/15
P/E TM
26.0x
Dividend
¥25.00
Dividend Yield
1.75%
Current Stock Chart for R-TECH UENO LTD (4573)

Related News

No related news articles were found.

r-tech ueno ltd (4573) Related Businessweek News

No Related Businessweek News Found

r-tech ueno ltd (4573) Details

R-Tech Ueno, Ltd. is engaged in the research, development, manufacture, and sale of pharmaceutical products for the treatment of ophthalmology and dermatology worldwide. The company offers Rescula eye drops to treat glaucoma and ocular hypertension. Its product pipeline comprises Rescula/UF-021, which is in Phase IIb clinical trials to treat retinitis pigmentosa; RU-101m which is in Phase I clinical trials for the treatment of dry eye; and RK-023 that is in Phase IIa clinical trials to treat alopecia, as well as in Phase I clinical trials to treat hypotrichosis of the eyelashes. The company is also developing RTU-007 for treating diabetic cataract and retinopathy, and age-related macula degeneration; RTU-1096 for the treatment of atopic dermatitis, contact dermatitis, psoriasis, and diabetic neuropathy. In addition, it offers R and D assistance services, including development of synthetic methods and contract manufacturing of drug substances; characterization studies; formulation studies; quality tests and stability evaluations for investigational drugs and test articles for safety studies; release tests and stability tests for drugs and establishment of drug specification for application; documentation for drug application; and provision of documents and other responses to regulatory authorities. Further, the company is engaged in contract manufacturing of eye drops, liquid drugs, and liquid-filled hard capsules. R-Tech Ueno, Ltd. was founded in 1989 and is headquartered in Tokyo, Japan.

Founded in 1989

r-tech ueno ltd (4573) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

r-tech ueno ltd (4573) Key Developments

R-Tech Ueno, Ltd., Annual General Meeting, Jun 24, 2014

R-Tech Ueno, Ltd., Annual General Meeting, Jun 24, 2014.

R-Tech Ueno, Ltd. Reports Earnings Results for the Fourth Quarter and Year Ended March 2014

R-Tech Ueno, Ltd. reported earnings results for the fourth quarter and year ended March 2014. For the quarter, the company’s net sales were ¥1,404 million, operating income was ¥337 million, ordinary income was ¥318 million and net income was ¥249 million. For the year, the company’s net sales were ¥5,618 million against ¥4,552 million a year ago. Operating income was ¥1,419 million against ¥784 million a year ago. Ordinary income was ¥1,477 million against ¥890 million a year ago. Net income was ¥1,062 million against ¥561 million a year ago. The increase in operating income is resulting from higher gross margin due to the above-mentioned overall sales increase, despite higher research and development expenses (Up 7.3% year-over-year) arising from the phase three clinical trials for the treatment of retinitis pigmentosa (Development code: UF-021) and early phase two clinical trials for ophthalmic solution to treat severe dry eye (Development code: RU-101).

R-Tech Ueno, Ltd., 2014 Earnings Call, May 20, 2014

R-Tech Ueno, Ltd., 2014 Earnings Call, May 20, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4573:JP ¥1,432.00 JPY +22.00

4573 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4573.
View Industry Companies
 

Industry Analysis

4573

Industry Average

Valuation 4573 Industry Range
Price/Earnings 26.2x
Price/Sales 4.9x
Price/Book 3.0x
Price/Cash Flow 25.7x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact R-TECH UENO LTD, please visit www.rtechueno.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.